Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Market Closed 11-06 16:00:00 EST

3.90

+0.29

+8.03%

盘后3.90

+0.000.00%

19:30 EST

High3.98	Low3.61	Vol3.53M
Open3.62	D1 Closing3.61	Amplitude10.10%
Mkt Cap620.10M	Tradable Cap425.10M	Total Shares159.00M
T/O13.58M	T/O Rate3.24%	Tradable Shares109.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":3.9,"timestamp":1793998800000,"preClose":3.61,"halted":0,"volume":3526373,"hourTrading":{"tag":"盘后","latestPrice":3.9,"preClose":3.9,"latestTime":"19:30 EST","volume":21668,"amount":84511.5721,"timestamp":1794011403291,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.08033240997229918,"floatShares":109000000,"shares":159000000,"eps":-0.586082,"marketStatus":"Market Closed","change":0.29,"latestTime":"11-06 16:00:00 EST","open":3.62,"high":3.975,"low":3.6104,"amount":13582004.0439738,"amplitude":0.100997,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.586082,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":3.61,"preHourTrading":{"tag":"盘前","latestPrice":3.7,"preClose":3.61,"latestTime":"08:50 EST","volume":1776,"amount":6235.7450352,"timestamp":1793973005196,"change":0.09,"changeRate":0.024931,"amplitude":0.257285},"postHourTrading":{"tag":"盘后","latestPrice":3.9,"preClose":3.9,"latestTime":"19:30 EST","volume":21668,"amount":84511.5721,"timestamp":1794011403291,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.805417,"impliedVol":0.5734,"impliedVolPercentile":0.0319},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2681607183","title":"Aclaris Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2681607183","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681607183?lang=en_us&edition=fundamental","pubTime":"2026-11-05 22:18","pubTimestamp":1793888317,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings SummaryAclaris Therapeutics, Inc.ACRS.OQreported a quarterly adjusted loss of 12 cents per share for the quarte","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL5N46M1VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681027947","title":"Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2681027947","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681027947?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:22","pubTimestamp":1793881361,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year.  The company","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62912961/aclaris-therapeutics-q3-eps-0-12-beats-0-16-estimate-sales-1-481m-beat-1-298m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681102275","title":"Aclaris Therapeutics Q3 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2681102275","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681102275?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:12","pubTimestamp":1793880775,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q3 revenue beats analyst estimatesOverviewUS biopharma firm's Q3 revenue declined yr/yr but beat analyst expectationsQ3 net loss widened yr/yr but was smaller than analysts expect","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0239","BK4539","IBRN","BK0046","BK0012","APRE","BK4505","300485","LYEL","ACRS","BK0028","DNTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681241610","title":"Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681241610","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681241610?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:00","pubTimestamp":1793880001,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 MillionNov 05 (Reuters) - Aclaris Therapeutics Q3 revenue USD 1.481 million vs. IBES estimate USD 1.3 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXB34CVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681024500","title":"Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2681024500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681024500?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:59","pubTimestamp":1793879940,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA63TKWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679288528","title":"Aclaris Therapeutics, Inc. : Canaccord Genuity Raises Target Price to $13 from $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2679288528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679288528?lang=en_us&edition=fundamental","pubTime":"2026-10-29 21:12","pubTimestamp":1793279560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nFWN46F3EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678493986","title":"Oppenheimer Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678493986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678493986?lang=en_us&edition=fundamental","pubTime":"2026-10-28 20:55","pubTimestamp":1793192130,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst reiterated a Buy rating on Aclaris Therapeutics today and set a price target of $10.00. In a report released today, H.C. Wainwr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678249837","title":"Wedbush Cuts Price Target on Aclaris Therapeutics to $8 From $10, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2678249837","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678249837?lang=en_us&edition=fundamental","pubTime":"2026-10-28 20:35","pubTimestamp":1793190910,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $10.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678461340","title":"Aclaris Therapeutics Price Target Maintained with a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2678461340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678461340?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:08","pubTimestamp":1793185680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678769911","title":"Aclaris Therapeutics prices 7.79M shares at $3.50 in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2678769911","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678769911?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:50","pubTimestamp":1793098218,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-prices-7-79m-shares-at-3-50-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-prices-7-79m-shares-at-3-50-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678173011","title":"Aclaris Therapeutics Prices $50 Million Stock and Pre-Funded Warrant Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2678173011","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678173011?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:44","pubTimestamp":1793097859,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Prices $50 Million Stock and Pre-Funded Warrant OfferingAclaris Therapeutics priced an underwritten offering expected to raise approximately $50 million in gross proceeds before f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL5LjYqq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","ACRS","IE00BQXX3C00.GBP","BCDF","IE00BN0W2W23.USD","BK4007","LU2095319765.USD","IE00BKPKM429.USD","BK4112","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678730951","title":"Aclaris Therapeutics - Prices 7,785,714 Shares of Common Stock at $3.5 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2678730951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678730951?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:43","pubTimestamp":1793097836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUA3L52XD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678173030","title":"Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2678173030","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678173030?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:43","pubTimestamp":1793097836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUA3L52XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678286120","title":"Aclaris Therapeutics - ATI-052 Demonstrates Favorable Safety Profile with no Grade 3 or 4 Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2678286120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678286120?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:09","pubTimestamp":1793095771,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nFWN46D0S5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678202821","title":"Aclaris Therapeutics - ATI-052 Shows 45% Placebo-Adj Mean Change in Easi Score at Day 57 in Ad Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678202821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678202821?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:09","pubTimestamp":1793095771,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nFWN46D0S5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678120668","title":"Aclaris Reports Positive Phase 1b Results for ATI-052 in Atopic Dermatitis, Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2678120668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678120668?lang=en_us&edition=fundamental","pubTime":"2026-10-27 18:02","pubTimestamp":1793095357,"startTime":"0","endTime":"0","summary":"Aclaris Reports Positive Phase 1b Results for ATI-052 in Atopic Dermatitis, AsthmaAclaris Therapeutics announced positive Phase 1b proof-of-concept results for ATI-052 in atopic dermatitis and asthma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDLc1QLzW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BK4007","IE00B64PRP62.GBP","BK4112","IE00BKPKM429.USD","ACRS","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU0314104364.USD","BK4585","LU2210150020.SGD","BK4588","BCDF","SG9999014021.USD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676688901","title":"Piper Sandler Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676688901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676688901?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:16","pubTimestamp":1792408599,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Aclaris Therapeutics, with a price target of $11.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672871167","title":"Aclaris Therapeutics management to meet virtually with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2672871167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672871167?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:50","pubTimestamp":1790801412,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on October 6 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-virtually-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-virtually-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871234","title":"Aclaris CEO Neal Walker Joins Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871234","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871234?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:01","pubTimestamp":1788436861,"startTime":"0","endTime":"0","summary":"Aclaris CEO Neal Walker joins Cantor Global Healthcare Conference fireside chatAclaris Therapeutics will join the 2026 Cantor Global Healthcare Conference on Sept. 10, 2026.CEO Neal Walker is schedule","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL6yyzRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","ACRS","IE00BQXX3C00.GBP","BCDF","IE00BN0W2W23.USD","BK4007","LU2095319765.USD","IE00BKPKM429.USD","BK4112","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664863495","title":"Aclaris Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2664863495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664863495?lang=en_us&edition=fundamental","pubTime":"2026-09-02 01:55","pubTimestamp":1788285300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":-0.0176},{"period":"1month","weight":0.1471},{"period":"3month","weight":-0.3401},{"period":"6month","weight":-0.2089},{"period":"1year","weight":0.7181},{"period":"ytd","weight":0.2957}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.021975},{"month":4,"riseRate":0.454545,"avgChangeRate":0.005147},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.034939},{"month":6,"riseRate":0.636364,"avgChangeRate":0.010279},{"month":7,"riseRate":0.545455,"avgChangeRate":0.007544},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.002973},{"month":9,"riseRate":0.363636,"avgChangeRate":0.012342},{"month":10,"riseRate":0.363636,"avgChangeRate":0.097957},{"month":11,"riseRate":0.333333,"avgChangeRate":0.067551},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}